James Gibson
Clinical Biochemical Genetics · Austin, TXNPI 1023121159
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,000 of the $7,413 with a category attached, or 67.5%. Mallinckrodt Enterprises LLC accounts for 89.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $6,726 and has fallen 97.7% since, to $155 in 2025.
Across 17 payments — averaging $436.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Enterprises LLC$7K
- Biomarin Pharmaceutical Inc.$407
- Zevra Therapeutics Inc$132
- Cycle Pharmaceuticals Inc$77
- Amicus Therapeutics, Inc.$70
- Sanofi$39
- plus $74 from 3 others
Across 201 payments — averaging $2935.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$268K
- Mallinckrodt Enterprises LLC$202K
- Travere Therapeutics, Inc.$100K
- Amgen$9K
- Mirum Pharmaceuticals, Inc.$6K
- Sanofi$4K
- plus $1K from 1 others
What the payments were for
- Consulting fees$5,00067%
- Speaking & faculty fees$3755%
- Travel & lodging$85612%
- Food & beverage$1,11115%
- Education$701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Enterprises LLC | 5 | $6,612 |
| Biomarin Pharmaceutical Inc. | 4 | $407 |
| Zevra Therapeutics Inc | 1 | $132 |
| Cycle Pharmaceuticals Inc | 1 | $77 |
| Amicus Therapeutics, Inc. | 1 | $70 |
| Sanofi | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Eton Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical biochemical genetics providers in Texasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VprivVelaglucerase Alfa | 25 | $635,245 |
| ChenodalChenodiol | 12 | $555,192 |
| Gabapentin | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other clinical biochemical genetics in Austin
- John OdomSan Antonio$1K
- Qin SunHouston$143
- Sarah ElseaHouston$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.